68378-96-1

Basic information

• Product Name: SODIUM NITRITE-15N
• Synonyms: SODIUM NITRITE-15N;SODIUM NITRITE-15N, 99 ATOM % 15N;Sodium nitrite-15N;15N Labeled sodium nitrite;Sodium nitrite-15N (15N, 98%+)
• CAS NO: 68378-96-1
• Molecular Formula: NNaO₂
• Molecular Weight: 70
• Product Categories: Alphabetical Listings;Q-S;Stable Isotopes;Aliphatics;Isotope Labelled Compounds;Miscellaneous Reagents
• Mol File: 68378-96-1.mol
• Article Data: 2

Chemical Properties

• Melting Point: 271 °C(lit.)
• Appearance: /
• CAS DataBase Reference: SODIUM NITRITE-15N(CAS DataBase Reference)
• NIST Chemistry Reference: SODIUM NITRITE-15N(68378-96-1)
• EPA Substance Registry System: SODIUM NITRITE-15N(68378-96-1)

Safety Data

• Hazard Codes: O,T,N
• Statements: 8-25-50
• Safety Statements: 45-61
• RIDADR: UN 1500 5.1/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 68378-96-1(Hazardous Substances Data)

Usage

Chemical Properties

SODIUM NITRITE-15N is Solid

Uses

Labelled analogue of SODIUM NITRITE-15N used in nitrite quantification in human whole blood, erythrocytes, and plasma.

InChI:InChI=1/HNO2.Na/c2-1-3;/h(H,2,3);/q;+1/p-1/i1+1;

Upstream product

• 1310-73-2 sodium hydroxide 
• 15917-77-8 ¹⁵N labeled nitric oxide 
• 31432-45-8 sodium (¹⁵N)nitrate 

Downstream Products

• 10024-97-2 dinitrogen monoxide 
• 14184-22-6 ⁽¹⁵⁾N-nitrogen dioxide 
• 7632-00-0 sodium nitrite 
• 31432-45-8 sodium (¹⁵N)nitrate 
• 20621-02-7 ⁽¹⁵⁾N-nitrous oxide 
• 35305-17-0 nitrous oxide 
• 20509-24-4 (14,15)NO 
• 15917-77-8 ¹⁵N labeled nitric oxide 
• 1173020-41-1 ⁽¹⁴⁾-nitrogen 

Relevant articles and documents

Higher-energy collision-induced dissociation for the quantification by liquid chromatography/tandem ion trap mass spectrometry of nitric oxide metabolites coming from S-nitroso-glutathione in an in vitro model of the intestinal barrier

Rationale: The potency of S-nitrosoglutathione (GSNO) as a nitric oxide (NO) donor to treat cardiovascular diseases (CVDs) has been highlighted in numerous studies. In order to study its bioavailability after oral administration, which represents the most convenient route for the chronic treatment of CVDs, it is essential to develop an analytical method permitting (i) the simultaneous measurement of GSNO metabolites, i.e. nitrite, S-nitrosothiols (RSNOs) and nitrate and (ii) to distinguish them from other sources (endogenous synthesis and diet). Methods: Exogenous GSNO was labeled with 15N, and the GS15NO metabolites after conversion into the nitrite ion were derivatized with 2,3-diaminonaphthalene. The resulting 2,3-naphthotriazole was quantified by liquid chromatography/tandem ion trap mass spectrometry (LC/ITMS/MS) in multiple reaction monitoring mode after Higher-energy Collision-induced Dissociation (HCD). Finally, the validated method was applied to an in vitro model of the intestinal barrier (monolayer of Caco-2 cells) to study GS15NO intestinal permeability. Results: A LC/ITMS/MS method based on an original transition (m/z 171 to 156) for sodium 15N-nitrite, GS15NO and sodium 15N-nitrate measurements was validated, with recoveries of 100.8 ± 3.8, 98.0 ± 2.7 and 104.1 ± 3.3%, respectively. Intra- and inter-day variabilities were below 13.4 and 12.6%, and the limit of quantification reached 5 nM (signal over blank = 4). The permeability of labeled GS15NO (10–100 μM) was evaluated by calculating its apparent permeability coefficient (Papp). Conclusions: A quantitative LC/ITMS/MS method using HCD was developed for the first time to selectively monitor GS15NO metabolites. The assay allowed evaluation of GS15NO intestinal permeability and situated this drug candidate within the middle permeability class according to FDA guidelines. In addition, the present method has opened the perspective of a more fundamental work aiming at studying the fragmentation mechanism leading to the ion at m/z 156 in HCD tandem mass spectrometry in the presence of acetonitrile.